Aquestive Therapeutics, Inc. · NASDAQ:AQST

Aquestive Therapeutics — Q3 2026 Earnings Presentation

13 slides from Aquestive Therapeutics's earnings presentation, Nov 4, 2026

  1. Slide 1: Third Quarter 2026 Earnings Supplemental Materials

    Third Quarter 2026 Earnings Supplemental Materials November 3, 2026

  2. Slide 2: Disclaimer

    Disclaimer These forward-looking statements include, but are not limited to, statements regarding the advancement and related timing of Anaphylm (dibutepinephrine) Sublingual Film through the FDA regulatory review and approval process; our ability to address the matters identified by the FDA in the

  3. Slide 3: Q3 2026 Earnings Key Messages

    Q3 2026 Earnings Key Messages Anaphylm (dibutepinephrine) sublingual film for severe allergic reactions, including anaphylaxis • Anaphylm New Drug Application (NDA) was resubmitted in Q3 2026 • PDUFA goal date is March 16, 2027 • Commercial launch preparations remain on track for a potential launch

  4. Slide 4: Lead Asset Anaphylm (dibutepinephrine) sublingual film

    Lead Asset Anaphylm (dibutepinephrine) sublingual film ANAPHYLM (dibutepinephrine) sublingual film is an investigational product candidate that has not been approved by the U.S. Food and Drug Administration. Safety and efficacy have not been established. Statements regarding potential benefits, clin

  5. Slide 5: Market Insights Inform Anaphylm Launch Planning

    Market Insights Inform Anaphylm Launch Planning¹  Build allergist awareness and confidence through scientific exchange and education  Communicate Anaphylm’s potential product differentiation, if approved  Incorporate patient and caregiver insights into education and support  Simplify access, ful

  6. Slide 6: Broad Scientific and Prescriber Engagement Builds Anaphylm Awareness

    Broad Scientific and Prescriber Engagement Builds Anaphylm Awareness¹ 50 Conferences 876+ 1090+ Booth Prescriber Attended & Planned Engagements interactions 14 Manuscripts 10 Conference drafted abstracts submitted 1. Year-to-date information. 6

  7. Slide 7: 96% of Survey Respondents Preferred Film in a Hands-on Preference Survey

    96% of Survey Respondents Preferred Film in a , Hands-on Preference Survey¹ ² Survey Results Survey Methodology: • Double-blinded survey with 27 adult patients and 26 caregivers of pediatric patients at risk for anaphylaxis 51 Anaphylm: Where • Respondents were mailed an envelope containing one You

  8. Slide 8: Upcoming Milestones and Third Quarter 2026 Results

    Upcoming Milestones and Third Quarter 2026 Results 8

  9. Slide 9: Recently Completed & Expected Key Milestones

    Recently Completed & Expected Key Milestones Q3 2026 Q4 2026 Q1 2027 Q2 2027 NDA Resubmitted Ex-US Filing in Canada PDUFA Goal Date Anaphylm Launch, Anaphylm March 16th if approved by FDA PDUFA Goal Dates in Libervant March AQST-108 Additional Clinical Studies 9

  10. Slide 10: Cash Management Remains On Track

    Cash Management Remains On Track Ending Cash Balance by Quarter $121.2 120 $110.7 $98.5 100 $90.3 USD (Millions) 80 60 40 20 0 Q4 25 Q1 26 Q2 26 Q3 26 10

  11. Slide 11: Quarterly Manufacturing Shipment Volumes

    Quarterly Manufacturing Shipment Volumes Doses Shipped by Quarter 60,000 50,000 47,250 47,909 45,328 43,838 43,801 DOSES SHIPPED (000’S) 42,516 43,032 40,000 37,204 34,418 33,320 30,000 27,262 25,831 20,000 10,000 0 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26 QUARTER 11

  12. Slide 12: 2026 Guidance as of November 3, 2026

    2026 Guidance as of November 3, 2026 2026 Outlook • Total revenues of approximately $46-$50 million • Non-GAAP adjusted EBITDA loss of approximately $35-$30 million 12

  13. Slide 13: Thank You

    Thank You re § Aque

Aquestive Therapeutics — Q3 2026 Earnings Presentation on 6ix